Overview

Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)

Status:
Completed
Trial end date:
2006-03-30
Target enrollment:
Participant gender:
Summary
The purpose of the study is to measure how effective and safe three different doses of the drug clazosentan are in preventing vasospasm after subarachnoid hemorrhage.
Phase:
Phase 2
Details
Lead Sponsor:
Actelion
Idorsia Pharmaceuticals Ltd.